help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhao, X.-Y.
Right arrow Articles by Feldman, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhao, X.-Y.
Right arrow Articles by Feldman, D.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Prostate Cancer
Endocrinology Vol. 141, No. 7 2548-2556
Copyright © 2000 by The Endocrine Society

ARTICLES

1{alpha},25-Dihydroxyvitamin D3 Inhibits Prostate Cancer Cell Growth by Androgen-Dependent and Androgen-Independent Mechanisms1

Xiao-Yan Zhao, Donna M. Peehl, Nora M. Navone and David Feldman

Departments of Medicine (X.-Y.Z., D.F.) and Urology (D.M.P.), Stanford University School of Medicine, Stanford, California 94305; and Department of GU Medical Oncology, University of Texas M. D. Anderson Cancer Center (N.M.N.), Houston, Texas 77030

Address all correspondence and requests for reprints to: David Feldman, M.D., Division of Endocrinology, Room S-005, Stanford University Medical Center, Stanford, California 94305-5103. E-mail: feldman{at}cmgm.stanford.edu

We recently reported that 1{alpha},25-dihydroxyvitamin D3 [1,25-(OH)2D3] inhibits the growth of the LNCaP human prostate cancer cell line by an androgen-dependent mechanism. In the present study we examined the actions and interactions of 1,25-(OH)2D3 and the androgen 5{alpha}-dihydrotestosterone (DHT) on two new human prostate cancer cell lines (MDA), MDA PCa 2a and MDA PCa 2b. Scatchard analyses revealed that both cell lines express high affinity vitamin D receptors (VDRs) with a binding affinity (Kd) for [3H]1,25-(OH)2D3 of 0.1 nM. However, the MDA cell lines contain low affinity androgen receptors (ARs) with a Kd of 25 nM for [3H]DHT binding. This is 50-fold lower than the AR in LNCaP cells (Kd = 0.5 nM). Their response to DHT is greatly reduced; 2a cells do not respond to 100 nM DHT, and 2b cells show a modest response at that high concentration. 1,25-(OH)2D3 causes significant growth inhibition in both MDA cell lines, greater (for 2b cells) or lesser (for 2a cells) than that in the LNCaP cell line. Moreover, 1,25-(OH)2D3 significantly up-regulates AR messenger RNA in all three cell lines, as shown by Northern blot analysis. The growth inhibitory effect of 1,25-(OH)2D3 on LNCaP cells is blocked by the pure antiandrogen, Casodex, as we previously reported. However, Casodex (at 1 µM) did not block the antiproliferative activity of 1,25-(OH)2D3 in MDA cells. In conclusion, the growth inhibitory action of 1,25-(OH)2D3 in the MDA cell lines appears to be androgen independent, whereas the actions of 1,25-(OH)2D3 in LNCaP cells are androgen dependent. Most importantly, the MDA cell lines, derived from a bone metastasis of human prostate carcinoma, remain sensitive to 1,25-(OH)2D3, a finding relevant to the therapeutic application of vitamin D and its low calcemic analogs in the treatment of advanced prostate cancer.




This article has been cited by other articles:


Home page
 J. Nutr.Home page
T. M. Chlon, D. A. Taffany, J. Welsh, and M. J. Rowling
Retinoids Modulate Expression of the Endocytic Partners Megalin, Cubilin, and Disabled-2 and Uptake of Vitamin D-Binding Protein in Human Mammary Cells
J. Nutr., July 1, 2008; 138(7): 1323 - 1328.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Kaeding, J. Belanger, P. Caron, M. Verreault, A. Belanger, and O. Barbier
Calcitrol (1{alpha},25-dihydroxyvitamin D3) inhibits androgen glucuronidation in prostate cancer cells
Mol. Cancer Ther., February 1, 2008; 7(2): 380 - 390.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
S. Wedren, C. Magnusson, K. Humphreys, H. Melhus, A. Kindmark, F. Stiger, M. Branting, I. Persson, J. Baron, and E. Weiderpass
Associations between Androgen and Vitamin D Receptor Microsatellites and Postmenopausal Breast Cancer
Cancer Epidemiol. Biomarkers Prev., September 1, 2007; 16(9): 1775 - 1783.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
H.-J. Ting, B.-Y. Bao, J. E. Reeder, E. M. Messing, and Y.-F. Lee
Increased Expression of Corepressors in Aggressive Androgen-Independent Prostate Cancer Cells Results in Loss of 1{alpha},25-Dihydroxyvitamin D3 Responsiveness
Mol. Cancer Res., September 1, 2007; 5(9): 967 - 980.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
L. Peng, P. J. Malloy, J. Wang, and D. Feldman
Growth Inhibitory Concentrations of Androgens Up-Regulate Insulin-Like Growth Factor Binding Protein-3 Expression via an Androgen Response Element in LNCaP Human Prostate Cancer Cells
Endocrinology, October 1, 2006; 147(10): 4599 - 4607.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
S. Nagpal, S. Na, and R. Rathnachalam
Noncalcemic Actions of Vitamin D Receptor Ligands
Endocr. Rev., August 1, 2005; 26(5): 662 - 687.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
L.-C. Li, P. R. Carroll, and R. Dahiya
Epigenetic Changes in Prostate Cancer: Implication for Diagnosis and Treatment
J Natl Cancer Inst, January 19, 2005; 97(2): 103 - 115.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Jung, R.-S. Kim, H.-J. Zhang, S.-J. Lee, and M.-H. Jeng
HOXB13 Induces Growth Suppression of Prostate Cancer Cells as a Repressor of Hormone-Activated Androgen Receptor Signaling
Cancer Res., December 15, 2004; 64(24): 9185 - 9192.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
M. F. McCarty
Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy
Integr Cancer Ther, December 1, 2004; 3(4): 349 - 380.
[Abstract] [PDF]

Home page
 Exp. Biol. Med.Home page
L. V. Stewart and N. L. Weigel
Vitamin D and Prostate Cancer
Experimental Biology and Medicine, April 1, 2004; 229(4): 277 - 284.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
D. M. Peehl, A. V. Krishnan, and D. Feldman
Pathways Mediating the Growth-Inhibitory Actions of Vitamin D in Prostate Cancer
J. Nutr., July 1, 2003; 133(7): 2461S - 2469.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Chen, M. Hewison, B. Hu, and J. S. Adams
Heterogeneous nuclear ribonucleoprotein (hnRNP) binding to hormone response elements: A cause of vitamin D resistance
PNAS, May 13, 2003; 100(10): 6109 - 6114.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. E. Taplin and S.-M. Ho
The Endocrinology of Prostate Cancer
J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3467 - 3477.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2000 by The Endocrine Society